LABD:NYE-Direxion Daily S&P Biotech Bear 3X Shares (USD)

ETF | Trading--Inverse Equity | NYE

Last Closing Price

USD 19.95


-0.34 (-1.68)%

Market Cap

USD 0.06B



Average Target Price

Average Analyst Rating


Fundamental Analysis



The investment seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry Index. The fund, under normal circumstances, invests in swap agreements, futures contracts, short positions or other financial instruments that, in combination, provide inverse (opposite) or short leveraged exposure to the index equal to at least 80% of the fund's net assets (plus borrowing for investment purposes). The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards (GICS). The fund is non-diversified.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price



Top Sectors


Top Regions


Valuation Growth & Performance

Share Volume

Relative Performance (Total Returns)

Relative Returns (From:    To: 2021-06-17 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Mer Price(Change) Market Cap
SH ProShares Short S&P500 0.90 %

-0.01 (-0.06%)

SDS ProShares UltraShort S&P500 0.91 %

+0.01 (+0.11%)

PSQ ProShares Short QQQ 0.95 %

-0.18 (-1.39%)

SPXU ProShares UltraPro Short S&P50.. 0.93 %

+0.02 (+0.10%)

SPXS Direxion Daily S&P 500 Bear 3X.. 1.09 %


SDOW ProShares UltraPro Short Dow30 0.95 %

+0.60 (+1.74%)

TZA Direxion Daily Small Cap Bear .. 1.10 %

+0.99 (+3.44%)

RWM ProShares Short Russell2000 0.95 %

+0.23 (+1.10%)

DOG ProShares Short Dow30 0.95 %

+0.21 (+0.61%)

QID ProShares UltraShort QQQ 0.95 %

-0.58 (-2.59%)


ETFs Containing LABD

Symbol Name Weight Mer Price(Change) Market Cap


Market Performance

  Market Performance vs.
Industry/Classification (Trading--Inverse Equity)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Capital Gain -21.05% 60% D- 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.05% 60% D- 4% F
Trailing 12 Months  
Capital Gain -76.42% 16% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -76.42% 16% F 1% F
Trailing 5 Years  
Capital Gain -99.75% 4% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.75% 4% F N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -59.14% 3% F N/A N/A
Dividend Return 0.48% 66% D 12% F
Total Return -58.66% 3% F N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.42% 31% F 39% F
Risk Adjusted Return -213.95% 6% F N/A N/A
Market Capitalization 0.06B 69% D+ 11% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.